Article Text

Download PDFPDF
995 Clinicopathological criteria of cervical cancer patients in a single center retrospective analytical study
  1. Alaa Ahmed Elzarkaa1,
  2. Mervat Aly Elsersy1,
  3. Mahmoud Melees1,
  4. Nourhan Kolaib2,
  5. Mohamed Mostafa Hafez1,
  6. Hayat Sharaf Alrimi1,
  7. Ahmed Abdelmajeed1,
  8. Azza Mohamed Darwish3 and
  9. Ahmed Eleba1
  1. 1GYN Oncology unit, Elshatby University Hospital, Alexandria, Egypt
  2. 2Pathology department, Alexandria University Hospital, Alexandria, Egypt
  3. 3Clinical oncology and nuclear medicine department, Alexandria University Hospital, Alexandria, Egypt


Introduction/Background Although most cervical cancer cases are caused by persistent high-risk human papilloma virus (HR-HPV) infection, non-human papilloma virus associated cervical cancer (NHPVA CC) is now considered an independent category. The study aimed to provide clinicopathological characteristics of NHPVA CC).

Methodology A retrospective cohort study of cervical cancer cases presented to a single GYN oncology unit between September 2019 and September 2023. Using p16 as a marker for HPV, cases were classified into HPV-associated cervical cancer (HPVA CC) and NHPVA CC. Clinicopathologic and epidemiological criteria were compared between both groups.

Results The total number of patients retrieved in the study was 99; NHPVA CC represented 21.2% of them. The mean age at the presentation of the NHPVA group is 58.57 which is considered older than the HPVA CC group of which the mean age is 53.63 (p=0.069). Regarding the FIGO stage, HPVA CC presents more frequently as early-stage cervical cancer (28.2% of HPVA CC presents at early stages vs. 4.2% of NHPVA CC, p = 0.022). NHPVA CC is more frequently diagnosed as early locally advanced stage cervical cancer (38.1% of NHPVA CC presents as early locally advanced CC vs. 12.8% of HPVA CC, p = 0.021). LN metastases were found more frequently among NHPVA CC than HPVA CC (57.1% of NHPVA CC present with LN metastasis vs. 33.3% of HPVA CC, p=0.046). Histopathological, adenocarcinoma was more presented in NHPVA CC (38.1% of NHPVA CC vs. 12.8% of HPVA CC, p = 0.021), unlike HPVA CC which mainly of the SCC type (82.1% of HPVA CC vs. 57.1% of NHPVA CC, p=0.038).

Conclusion NHPVA CC represents a significant proportion of cervical cancer patients in our community, and it has its clinic-pathological criteria which raises attention that it might have different pathogenesis of cervical cancer development.

Disclosures The authors declare no conflict of interest. This research received no external funding.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.